Personalized medicine for advanced biliary cancer patients
- Conditions
- Advanced Biliary Cancer (ABC)MedDRA version: 20.0Level: LLTClassification code: 10028982Term: Neoplasm biliary tract Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-508100-38-00
- Lead Sponsor
- nicancer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 559
Screening phase - Signed a written informed consent form prior to any trial specific procedures (Consent #1), Randomised trial - Signed a written informed consent form prior to any trial specific procedures (Consent #2), Randomised trial - Molecular profile showing the tumour harbours at least one targetable molecular alteration with a MTT in the study portfolio (as determined by the trial MTB), Randomised trial - Disease control (stable or responsive) after 4 cycles of 1L-SoC, compared to a pretreatment disease evaluation, as assessed by the investigator, Randomised trial - ECOG performance status of 0 or 1, Randomised trial - Presence of at least one evaluable lesion according to RECIST v1.1, or complete response to 12 weeks 1L-SoC, Randomised trial - Adequate bone marrow function: absolute neutrophil count (ANC) =1.5 × 10?/L, platelet count =100 × 10?/L, and haemoglobin =9 g/dL, Randomised trial - Adequate liver function: total bilirubin level =1.5 × the upper limit of normal (ULN) range unless the patient has documented Gilbert syndrome, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =2.5 × ULN (AST and ALT =5 ULN when documented tumour liver involvement), Randomised trial - Adequate renal function: estimated creatinine clearance =45 mL/min according to the Cockcroft-Gault formula, Randomised trial - Adequate cardiac function: left ventricular ejection fraction =50% at baseline as determined by either echocardiogram or multigated acquisition scan (MUGA), Randomised trial - Adequate biliary drainage, with no evidence of ongoing infection, Screening phase - Histologically-proven intrahepatic, perihilar or distal cholangiocarcinoma, or gallbladder carcinoma (ampullary carcinoma excluded), Randomised trial - Men, and women of childbearing potential (WOCBP) must agree to use adequate contraception for the duration of trial participation and as required after completing study treatment. Men must also agree to not donate sperm and women must agree to not donate oocytes during the specified period., Randomised trial - Women of childbearing potential must have a negative serum pregnancy test performed within 3 days before the date of randomisation, Randomised trial - Willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests, and other study procedures, Randomised trial - Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements), Screening phase - De novo or recurrent, locally advanced (non-resectable) or metastatic disease, Screening phase - Availability of a suitable archived sample of primary or metastatic tumour tissue (frozen, or FFPE) or able to undergo a biopsy to obtain a suitable malignant tissue sample, Screening phase - Aged =18 years, Screening phase - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Screening phase - Estimated life expectancy >3 months, Screening phase - Candidate for 1L-SoC therapy, or has initiated first cycle of 1L-SoC therapy, Screening phase - Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements).
Screening phase - Contraindication to 1L-SoC, Screening phase - Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons, Randomised trial - Disease progression occurring at any time prior randomisation, or toxicity that led to the discontinuation of the 1L-SoC before 4 full cycles have been delivered, Randomised trial - Toxicities from 1L-SoC not resolved to Grade = 2 (according to version 5.0 the National Cancer Institute - Common terminology criteria for adverse events [NCI-CTCAE v5.0]) before randomisation, with the exception of alopecia, Randomised trial - Contraindication or known hypersensitivity to the MTT for the molecular alteration found in the patient, or any component in their formulation, Randomised trial - Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancers, Randomised trial - Major surgery within 4 weeks of randomisation, Randomised trial - Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed, Randomised trial - Known leptomeningeal disease. If leptomeningeal disease has been reported radiographically on baseline magnetic responance imaging (MRI), but is not suspected clinically by the investigator, the subject must be free of neurological symptoms., Randomised trial - Concurrent malignancy (other than ABC), with the exception of adequately treated conebiopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 5 years or more and are deemed at negligible risk for recurrence, are eligible for the trial, Randomised trial - Known active hepatitis B virus or hepatitis C virus infection or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome, Screening phase - Individuals deprived of liberty or placed under protective custody or guardianship, Randomised trial - Any condition which in the Investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol, Randomised trial - Women who are pregnant or breast-feeding, Randomised trial - Participation in another therapeutic trial within the 30 days prior to entering the study. Participation in an observational trial would be acceptable, Randomised trial - Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons, Randomised trial - Individuals deprived of liberty or placed under protective custody or guardianship, For patients assigned to receive oral therapies - Inability or unwillingness to swallow pills, For patients assigned to receive oral therapies - History of malabsorption syndrome or other condition that would interfere with enteral absorption., Screening phase - Patients who are candidates for locoregional therapy, Screening phase - Contraindication to tumour biopsy in the absence of suitable archived sample of tumour tissue, Screening phase - Prior anticancer therapy in the palliative setting. Adjuvant capecitabine allowed if completed = 183 days prior to study entry, Screening phase - Received more than 1 cycle of treatment with 1L
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method